Spontaneous tumor regression and immunotherapy response demonstrate clonal T-cell expansion in Merkel cell carcinoma.
NPJ Precis Oncol.
2025 Jul 1;9(1):212. doi: 10.1038/s41698-025-00987-6. PubMed PMID:
40594889; PubMed Central PMCID:
PMC12218097.
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer.
J Immunother Cancer.
2025 Jun 22;13(6). doi: 10.1136/jitc-2024-010851. PubMed PMID:
40550568; PubMed Central PMCID:
PMC12184344.
Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control.
J Immunother Cancer.
2025 May 13;13(5). doi: 10.1136/jitc-2024-011378. PubMed PMID:
40360436; PubMed Central PMCID:
PMC12163335.
Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors.
Int J Mol Sci.
2025 May 6;26(9). doi: 10.3390/ijms26094394. Review. PubMed PMID:
40362635; PubMed Central PMCID:
PMC12072705.
Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy.
J Immunother Cancer.
2025 May 2;13(5). doi: 10.1136/jitc-2024-011074. PubMed PMID:
40316302; PubMed Central PMCID:
PMC12049950.
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial.
JAMA Oncol.
2025 Apr 1;11(4):394-399. doi: 10.1001/jamaoncol.2024.6998. PubMed PMID:
39976981; PubMed Central PMCID:
PMC11843463.
PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.
Lancet Respir Med.
2025 Apr;13(4):318-326. doi: 10.1016/S2213-2600(24)00368-0. Epub 2025 Jan 21. PubMed PMID:
39855244; PubMed Central PMCID:
PMC11968209.
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer.
Cancer Immunol Immunother.
2025 Mar 21;74(5):155. doi: 10.1007/s00262-025-04009-z. PubMed PMID:
40116923; PubMed Central PMCID:
PMC11928712.
Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection.
Oncologist.
2025 Mar 10;30(3). doi: 10.1093/oncolo/oyaf006. PubMed PMID:
40156838; PubMed Central PMCID:
PMC11954585.
Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammation.
Front Immunol.
2025;16:1432927. doi: 10.3389/fimmu.2025.1432927. eCollection 2025. PubMed PMID:
40103819; PubMed Central PMCID:
PMC11914793.
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
Cancer Res.
2025 Jan 2;85(1):134-153. doi: 10.1158/0008-5472.CAN-24-0133. PubMed PMID:
39388307; PubMed Central PMCID:
PMC11695179.
Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC.
Hepatology.
2025 Jan 1;81(1):32-43. doi: 10.1097/HEP.0000000000001054. Epub 2024 Aug 13. PubMed PMID:
39141577; PubMed Central PMCID:
PMC11643128.
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.
JAMA.
2024 Dec 10;332(22):1924-1935. doi: 10.1001/jama.2024.19462. Review. PubMed PMID:
39495525; PubMed Central PMCID:
PMC11808657.
Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.
Cancers (Basel).
2024 Nov 24;16(23). doi: 10.3390/cancers16233931. PubMed PMID:
39682120; PubMed Central PMCID:
PMC11640466.
Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants.
J Immunother Cancer.
2024 Nov 18;12(11). doi: 10.1136/jitc-2024-009868. PubMed PMID:
39557544; PubMed Central PMCID:
PMC11574437.
Correction to: Augmentation of tumor expression of HLADR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses.
J Transl Med.
2024 Sep 11;22(1):836. doi: 10.1186/s12967-024-05514-y. PubMed PMID:
39261932; PubMed Central PMCID:
PMC11391589.
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics.
Nat Cancer.
2024 Sep;5(9):1305-1317. doi: 10.1038/s43018-024-00793-2. Epub 2024 Jul 3. PubMed PMID:
38961276.
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
J Clin Oncol.
2024 Sep 1;42(25):3033-3046. doi: 10.1200/JCO.23.02233. Epub 2024 Jul 2. PubMed PMID:
38954785; PubMed Central PMCID:
PMC11361361.
TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice.
iScience.
2024 Aug 16;27(8):110520. doi: 10.1016/j.isci.2024.110520. eCollection 2024 Aug 16. PubMed PMID:
39139402; PubMed Central PMCID:
PMC11321305.
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
Eur Urol Oncol.
2024 Aug;7(4):735-741. doi: 10.1016/j.euo.2023.09.010. Epub 2023 Oct 17. PubMed PMID:
37858437; PubMed Central PMCID:
PMC11021375.
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines.
J Immunother Cancer.
2024 Jul 8;12(7). doi: 10.1136/jitc-2024-009595. PubMed PMID:
38977329; PubMed Central PMCID:
PMC11256020.
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020.
J Natl Cancer Inst.
2024 Jul 1;116(7):1063-1071. doi: 10.1093/jnci/djae018. PubMed PMID:
38374401; PubMed Central PMCID:
PMC11223850.
Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol.
J Gastrointest Oncol.
2024 Jun 30;15(3):1348-1354. doi: 10.21037/jgo-24-71. Epub 2024 Jun 20. PubMed PMID:
38989414; PubMed Central PMCID:
PMC11231869.
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision.
J Immunother Cancer.
2024 Jun 19;12(6). doi: 10.1136/jitc-2024-009063. Review. PubMed PMID:
38901879; PubMed Central PMCID:
PMC11191773.
Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study.
Acad Radiol.
2024 Jun;31(6):2424-2433. doi: 10.1016/j.acra.2024.01.009. Epub 2024 Jan 22. PubMed PMID:
38262813; PubMed Central PMCID:
PMC11214604.
Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses.
J Transl Med.
2024 May 31;22(1):524. doi: 10.1186/s12967-024-05339-9. PubMed PMID:
38822345; PubMed Central PMCID:
PMC11140921.
Utility of Large Language Models for Health Care Professionals and Patients in Navigating Hematopoietic Stem Cell Transplantation: Comparison of the Performance of ChatGPT-3.5, ChatGPT-4, and Bard.
J Med Internet Res.
2024 May 17;26:e54758. doi: 10.2196/54758. PubMed PMID:
38758582; PubMed Central PMCID:
PMC11143389.
Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.
Oncotarget.
2024 May 7;15:288-300. doi: 10.18632/oncotarget.28583. PubMed PMID:
38712741; PubMed Central PMCID:
PMC11075367.
Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study.
Oncologist.
2024 May 3;29(5):407-414. doi: 10.1093/oncolo/oyae009. PubMed PMID:
38309720; PubMed Central PMCID:
PMC11067804.
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence.
Front Oncol.
2024;14:1376622. doi: 10.3389/fonc.2024.1376622. eCollection 2024. PubMed PMID:
38741774; PubMed Central PMCID:
PMC11089222.
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Clin Cancer Res.
2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872. PubMed PMID:
37910044; PubMed Central PMCID:
PMC11018485.
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.
J Immunother Cancer.
2024 Mar 13;12(3). doi: 10.1136/jitc-2023-008480. PubMed PMID:
38485188; PubMed Central PMCID:
PMC10941133.
Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine.
Front Oncol.
2023;13:1321318. doi: 10.3389/fonc.2023.1321318. eCollection 2023. PubMed PMID:
38260854; PubMed Central PMCID:
PMC10802843.
Health diplomacy in action: The cancer legacy of the Good Friday Agreement.
J Cancer Policy.
2023 Dec;38:100448. doi: 10.1016/j.jcpo.2023.100448. Epub 2023 Oct 14. PubMed PMID:
37839622.
A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity.
Sci Transl Med.
2023 Nov 29;15(724):eadi0258. doi: 10.1126/scitranslmed.adi0258. Epub 2023 Nov 29. PubMed PMID:
38019931; PubMed Central PMCID:
PMC11421222.
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Cancer Treat Rev.
2023 Nov;120:102623. doi: 10.1016/j.ctrv.2023.102623. Epub 2023 Sep 9. PubMed PMID:
37716332; PubMed Central PMCID:
PMC10591840.
Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study.
medRxiv.
2023 Oct 31;. doi: 10.1101/2023.10.31.23297825. PubMed PMID:
38076813; PubMed Central PMCID:
PMC10705618.
Prediction of cancer treatment response from histopathology images through imputed transcriptomics.
Res Sq.
2023 Sep 15;. doi: 10.21203/rs.3.rs-3193270/v1. PubMed PMID:
37790315; PubMed Central PMCID:
PMC10543028.
Avelumab in Patients With Metastatic Colorectal Cancer.
Oncologist.
2023 Sep 7;28(9):823-e804. doi: 10.1093/oncolo/oyad162. PubMed PMID:
37310790; PubMed Central PMCID:
PMC10485289.
Applications of large language models in cancer care: current evidence and future perspectives.
Front Oncol.
2023;13:1268915. doi: 10.3389/fonc.2023.1268915. eCollection 2023. Review. PubMed PMID:
37731643; PubMed Central PMCID:
PMC10507617.
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Oncologist.
2023 Jul 5;28(7):642-e561. doi: 10.1093/oncolo/oyad058. PubMed PMID:
37134294; PubMed Central PMCID:
PMC10322134.
The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor.
Pediatr Blood Cancer.
2023 Jun 22;:e30358. doi: 10.1002/pbc.30358. [Epub ahead of print] PubMed PMID:
37347686; PubMed Central PMCID:
PMC10739575.
Vaccinating against cancer: getting to prime time.
J Immunother Cancer.
2023 Jun;11(6). doi: 10.1136/jitc-2022-006628. Review. PubMed PMID:
37286302; PubMed Central PMCID:
PMC10254974.
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
J Clin Invest.
2023 Jun 1;133(11). doi: 10.1172/JCI172059. PubMed PMID:
37259923; PubMed Central PMCID:
PMC10231984.
Adaptive Immunity in Genitourinary Cancers.
Eur Urol Oncol.
2023 Jun;6(3):263-272. doi: 10.1016/j.euo.2023.03.002. Epub 2023 Apr 15. Review. PubMed PMID:
37069029.
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
J Clin Pharmacol.
2023 Jun;63(6):672-680. doi: 10.1002/jcph.2203. Epub 2023 Feb 8. PubMed PMID:
36624662; PubMed Central PMCID:
PMC10175103.
Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy.
Clin Cancer Res.
2023 Jun 1;29(11):2025-2033. doi: 10.1158/1078-0432.CCR-21-3750. PubMed PMID:
36598437; PubMed Central PMCID:
PMC10238558.
The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance.
bioRxiv.
2023 May 3;. doi: 10.1101/2023.05.03.537252. PubMed PMID:
37205442; PubMed Central PMCID:
PMC10187243.
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
J Immunother Cancer.
2023 May;11(5). doi: 10.1136/jitc-2022-005813. PubMed PMID:
37236636; PubMed Central PMCID:
PMC10230972.
Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine.
J Immunother.
2023 May 1;46(4):145-151. doi: 10.1097/CJI.0000000000000459. Epub 2023 Feb 24. PubMed PMID:
36821354; PubMed Central PMCID:
PMC10072211.
What would you like to do?